Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan

被引:0
|
作者
Shibata, Yasushi [1 ]
Sato, Hiroshige [2 ]
Sato, Akiko [3 ]
Harada, Yoichi [4 ]
机构
[1] Univ Tsukuba, Mito Med Ctr, Dept Neurosurg, Mito 3100015, Japan
[2] Sato Clin Internal Med & Neurosurg, Dept Neurosurg, Moriya, 6750115, Japan
[3] Sato Clin Internal Med & Neurosurg, Dept Neurol, Moriya 3020117, Japan
[4] Mito Brain Heart Ctr, Dept Neurosurg, Mito 3100004, Japan
来源
NEUROLOGY INTERNATIONAL | 2024年 / 16卷 / 03期
关键词
migraine; triptan; lasmiditan; step care; CGRP;
D O I
10.3390/neurolint16030048
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50% at 1 h, patients took 50 mg of lasmiditan within 2 h of migraine onset. Patients recorded headache intensity and adverse events (AEs) caused by lasmiditan at 1, 2, and 4 h after the intake of an additional 50 mg of lasmiditan. A significant reduction in pain scale was observed post 50 mg lasmiditan intake (p < 0.001, t-test). Pain relief was reported for 32 migraine attacks (80%) at 1 h after additional lasmiditan intake. Although AEs were observed in 63% of the patients who took an additional lasmiditan, most were mild and resolved 1 h after lasmiditan intake. Our study revealed the significant headache relief provided by an additional lasmiditan for patients who did not achieve satisfactory results following initial triptan intake for treating migraine. The AEs associated with this treatment strategy were mild and lasted for a short time. This study suggested that the combination of triptan and lasmiditan is promising for the treatment of migraine and should be studied in a randomized placebo-controlled trial.
引用
收藏
页码:643 / 652
页数:10
相关论文
共 50 条
  • [21] Pharmacology and efficacy of eletriptan for the treatment of migraine attacks
    Diener, HC
    McHarg, A
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (10) : 670 - 674
  • [22] Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks
    Tepper, Stewart J.
    Vasudeva, Raghavendra
    Krege, John H.
    Rathmann, Suchitrita S.
    Doty, Erin
    Vargas, Bert B.
    Magis, Delphine
    Komori, Mika
    HEADACHE, 2020, 60 (08): : 1601 - 1615
  • [23] Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis
    Maiti, Rituparna
    Mishra, Archana
    Puliappadamb, Haridas Mundot
    Jena, Monalisa
    Srinivasan, Anand
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (12): : 1534 - 1544
  • [24] The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies
    Zhu, Hui
    Tang, Yongguo
    Zhou, Ting
    Song, Jing
    CLINICAL NEUROPHARMACOLOGY, 2020, 43 (06) : 191 - 195
  • [25] Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks
    Bussone, G
    Manzoni, GC
    Cortelli, P
    Roncolato, M
    Fabbri, L
    Benassuti, C
    NEUROLOGICAL SCIENCES, 2000, 21 (05) : 272 - 278
  • [26] Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain
    Peres, Mario F. P.
    Vasudeva, Raghavendra
    Baygani, Simin K.
    Dennehy, Ellen B.
    Vincent, Maurice
    Friedman, Deborah I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (06) : 1031 - 1038
  • [27] Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks
    G. Bussone
    G.C. Manzoni
    P. Cortelli
    M. Roncolato
    L. Fabbri
    C. Benassuti
    Neurological Sciences, 2000, 21 : 272 - 278
  • [28] Cerebral Hemodynamic Changes During Migraine Attacks and After Triptan Treatments
    Ozturk, Bilgin
    Karadas, Omer
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2020, 57 (03): : 192 - 196
  • [29] Triptan efficacy in migraine attacks: From appropriate diagnosis to metabolic profiles and pharmacogenomics
    Buzzi, M. Gabriella
    DRUG DEVELOPMENT RESEARCH, 2007, 68 (06) : 335 - 340
  • [30] TREATMENT OF MIGRAINE ATTACKS
    TFELTHANSEN, P
    NEW TRENDS IN CLINICAL NEUROPHARMACOLOGY: CALCIUM ANATONISTS, ACUTE NEUROLOGY, HEADACHE AND MOVEMENT DISORDERS, 1988, 7 : 197 - 202